» Articles » PMID: 34011337

The Statistical Approach in Trial-based Economic Evaluations Matters: Get Your Statistics Together!

Overview
Publisher Biomed Central
Specialty Health Services
Date 2021 May 20
PMID 34011337
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Baseline imbalances, skewed costs, the correlation between costs and effects, and missing data are statistical challenges that are often not adequately accounted for in the analysis of cost-effectiveness data. This study aims to illustrate the impact of accounting for these statistical challenges in trial-based economic evaluations.

Methods: Data from two trial-based economic evaluations, the REALISE and HypoAware studies, were used. In total, 14 full cost-effectiveness analyses were performed per study, in which the four statistical challenges in trial-based economic evaluations were taken into account step-by-step. Statistical approaches were compared in terms of the resulting cost and effect differences, ICERs, and probabilities of cost-effectiveness.

Results: In the REALISE study and HypoAware study, the ICER ranged from 636,744€/QALY and 90,989€/QALY when ignoring all statistical challenges to - 7502€/QALY and 46,592€/QALY when accounting for all statistical challenges, respectively. The probabilities of the intervention being cost-effective at 0€/ QALY gained were 0.67 and 0.59 when ignoring all statistical challenges, and 0.54 and 0.27 when all of the statistical challenges were taken into account for the REALISE study and HypoAware study, respectively.

Conclusions: Not accounting for baseline imbalances, skewed costs, correlated costs and effects, and missing data in trial-based economic evaluations may notably impact results. Therefore, when conducting trial-based economic evaluations, it is important to align the statistical approach with the identified statistical challenges in cost-effectiveness data. To facilitate researchers in handling statistical challenges in trial-based economic evaluations, software code is provided.

Citing Articles

Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin.

Ugalde A, Tothill R, Quinn S, Wong H, Prall O, Mitchell C BMC Cancer. 2025; 25(1):171.

PMID: 39881222 PMC: 11776227. DOI: 10.1186/s12885-025-13506-4.


Three-month outcomes and cost-effectiveness of interferon gamma-1b in critically ill patients: a secondary analysis of the PREV-HAP trial.

Bouras M, Tessier P, Poulain C, Schirr-Bonnans S, Roquilly A J Intensive Care. 2024; 12(1):40.

PMID: 39394183 PMC: 11468134. DOI: 10.1186/s40560-024-00753-z.


A pragmatic cluster randomised controlled trial of air filtration to prevent symptomatic winter respiratory infections (including COVID-19) in care homes (AFRI-c) in England: Trial protocol.

Brierley R, Taylor J, Turner N, Rees S, Thorn J, Metcalfe C PLoS One. 2024; 19(7):e0304488.

PMID: 39042618 PMC: 11265654. DOI: 10.1371/journal.pone.0304488.


The NCC mathematical modeling framework for decision-making of six major cancers.

Xia C, Chen W J Natl Cancer Cent. 2024; 3(1):35-47.

PMID: 39036317 PMC: 11256528. DOI: 10.1016/j.jncc.2022.11.002.


Cost-effectiveness analysis of health tapestry, a complex primary care program for older adults: a post-hoc analysis.

Tarride J, Blackhouse G, Lamarche L, Forsyth P, Oliver D, Carr T BMC Prim Care. 2024; 25(1):235.

PMID: 38961340 PMC: 11223344. DOI: 10.1186/s12875-024-02475-5.


References
1.
Thompson S, Barber J . How should cost data in pragmatic randomised trials be analysed?. BMJ. 2000; 320(7243):1197-200. PMC: 1127588. DOI: 10.1136/bmj.320.7243.1197. View

2.
de Wit M, Rondags S, van Tulder M, Snoek F, Bosmans J . Cost-effectiveness of the psycho-educational blended (group and online) intervention HypoAware compared with usual care for people with Type 1 and insulin-treated Type 2 diabetes with problematic hypoglycaemia: analyses of a cluster-randomized.... Diabet Med. 2017; 35(2):214-222. DOI: 10.1111/dme.13548. View

3.
Grieve R, Nixon R, Thompson S . Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials. Med Decis Making. 2009; 30(2):163-75. DOI: 10.1177/0272989X09341752. View

4.
Mason A, Gomes M, Grieve R, Carpenter J . A Bayesian framework for health economic evaluation in studies with missing data. Health Econ. 2018; 27(11):1670-1683. PMC: 6220766. DOI: 10.1002/hec.3793. View

5.
Barber J, Thompson S . Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy. 2004; 9(4):197-204. DOI: 10.1258/1355819042250249. View